INTRODUCTION
============

Kidney transplantation is the preeminent treatment for chronic kidney disease and end-stage renal disease. Not only does the living kidney donation help to reduce the number of patients waiting for an organ donation, but it also has---regarding the graft function---decisive advantages over cadaveric kidney grafts.^[@B1]^Nevertheless, living donor nephrectomy is a surgical challenge because the operation is performed in a healthy individual. Laparoscopic donor nephrectomy (LDN) offers less postoperative pain, a quicker convalescence, and a better cosmetic result than open nephrectomy, thus possibly increasing the number of renal donors.^[@B2]^ However, the LDN technique itself has drawbacks, such as a longer operative time and warm ischemia time, as well as possibly a higher rate of complications.^[@B3]^ Moreover, it has been criticized for some risk factors, including incisional hernia, bowel obstruction, and intraoperative massive hemorrhage.^[@B4],[@B5]^

Carbon dioxide (CO~2~) pneumoperitoneum, which may alter normal physiology and may affect kidney function and post-transplant immunity, have been widely used in LDN.^[@B6],[@B7]^ Recently, it has been shown in animals that pneumoperitoneum can increase the messenger RNA expression of endothelin-1, a potent vasoconstrictor that is implicated in the pathogenesis of ischemic pain and inflammation, by the kidney.^[@B8]^ CO~2~ pneumoperitoneum can induce stress responses with increased levels of tumor necrosis factor α, interleukin 6, and heat shock protein 70 in the serum,^[@B9]^ and oxidative stress markers (ischemia-modified albumin) were increased.^[@B10]^ These studies describe the differential expression of 1 gene or a few genes known to be associated with ischemia, injury, and fibrosis. However, there is little information on global gene expression in tissues associated with laparoscopic interventions. In addition, although there are several drugs for kidney diseases, such as atorvastatin,^[@B11]^ erythropoietin,^[@B12]^ and activated vitamin D,^[@B13]^ there is still an urgent need to discover novel drugs for the treatment of these diseases more effectively and selectively.

In this study we compared the gene expression profiles from kidneys recovered by LDN with CO~2~ pneumoperitoneum with those of open donor control kidneys and identified small-molecule drugs for kidney diseases by a bioinformatics approach. Our findings provide more knowledge about kidney diseases and may help researchers understand the underlying mechanism profoundly. Meanwhile, this study could contribute to the treatment of kidney diseases.

MATERIALS AND METHODS
=====================

Source of Data
--------------

The expression profile GSE3297^[@B14]^ was downloaded from the GEO (Gene Expression Omnibus) database based on the GPL96 platform. A total of 12 healthy adult kidney donors signed consent forms and were approved for donation according to the usual evaluation and practice of the Cleveland Clinic Renal Transplant Program. To avoid potentially significant differences in gene expression due to race, only white recipients were selected for our study. The 12 patients were divided into 2 groups, and general anesthesia and diuresis were performed in each patient. The 6 control patients underwent an extraperitoneal flank incision with only minimal manipulation of the kidney, and 2 subcapsular core renal biopsy specimens were obtained with a 15-gauge spring-loaded needle. For the 6 LDN cases, 2 core renal biopsy specimens were obtained with the same needles after the kidneys underwent 2 to 3 hours of CO~2~ pneumoperitoneum.

Data Preprocessing and Differentially Expressed Gene Analysis
-------------------------------------------------------------

The original data in CEL files were converted into identifiable expression form, and the missing data were imputed.^[@B15]^ Then, the complemented data were normalized.^[@B16]^

The Limma package in R language was used to identify the differentially expressed genes (DEGs) between control kidneys and LDN kidneys.^[@B17]^ The genes with a logFC \>1 and *P* \< .01 were considered differentially expressed.

Construction of Interaction Networks of DEGs
--------------------------------------------

In this study Osprey software was used to screen for all the interactions among DEGs and construct an interaction network.^[@B18]^ Osprey is a network visualization system that not only represents interactions in a flexible and rapidly expandable graphical format but also provides options for functional comparisons between datasets. This system integrates with BIND (Bimolecular Interaction Network Database)^[@B19]^ and GRID (General Repository for Interaction Database),^[@B20]^ which include 50,000 interactions.

Functional Enrichment Analysis for Interaction Network
------------------------------------------------------

Gene enrichment analysis is a promising high-throughput strategy that increases the likelihood for investigators to identify biological processes most pertinent to their study.^[@B21]^ DAVID (Database for Annotation, Visualization, and Integrated Discovery), which consists of an integrated biological knowledge base and analytic tools aimed at systematically extracting biological meaning from large gene or protein lists, is one of the most popular tools for enrichment analysis.^[@B22]^

In this study the DEGs in the network underwent functional enrichment analysis by DAVID and a hypergeometric algorithm. *P* \< .05 was set as the threshold.

Pathway Enrichment Analysis for Interaction Network
---------------------------------------------------

FuncAssociate is a Web application that discovers properties enriched in lists of genes or proteins that emerge from large-scale experimentation.^[@B23]^ In this study the DEGs in the interaction network were mapped into FuncAssociate, and *P* \< .05 was set as the threshold.

Screening for Small-Molecule Drugs
----------------------------------

The Connectivity Map (CMap) is a large public database that contains data on 7056 gene expression profiles and 6100 small-molecule treatment-control pairs. The CMap can be used to find connections among small molecules, diseases, and drugs.^[@B24]^ The up-regulated and down-regulated DEGs were mapped into CMap, and the small molecules with the absolute value of scores \>0.8 were identified.

RESULTS
=======

DEG Analysis Between Control Kidneys and LDN Kidneys
----------------------------------------------------

We obtained publicly available microarray dataset GSE3297 from the GEO database. After preprocessing and normalization, a total of 285 DEGs, which included 148 down-regulated genes and 137 up-regulated genes, were identified with *P* \< .01 and logFC \>1 (**[Figure 1](#F1){ref-type="fig"}**).

![Box plots were generated using the normalized data of 6 donor kidneys from open nephrectomy and 6 kidneys removed after LDN and several hours of CO~2~ pneumoperitoneum. The light-green and dark-green boxes indicate the control and LDN samples, respectively. The black line in each box represents the median of each sample. All the black lines are almost in the same position, which indicates minimum variability in these datasets.](jls0011432660001){#F1}

Construction of Interaction Network
-----------------------------------

Osprey software was used to analyze the interactions of DEG protein products and establish a DEG associated network. The interaction network, which contained 89 DEGs, is shown in **[Figure 2](#F2){ref-type="fig"}**.

![DEG associated interaction network.](jls0011432660002){#F2}

Functional Enrichment Analysis
------------------------------

As shown in **[Table 1](#T1){ref-type="table"}**, a total of 13 significantly enriched Gene Ontology (GO) terms were identified and the most significant term was response to steroid hormone stimulus (GO 0048545, *P* = .001). Several DEGs, including *CASP6*, *KRAS*, *SOCS1*, *ESR1*, *TSHB*, *COL1A1*, and *MMP14*, were in this term.

###### 

Functional Enrichment Results of the Interaction Network

  GO Term   Description                                              Genes                                                                                                               *P* Value
  --------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- -----------
  0048545   Response to steroid hormone stimulus                     *CASP6*, *KRAS*, *SOCS1*, *ESR1*, *TSHB*, *COL1A1*, *MMP14*                                                         .001
  0051129   Negative regulation of cellular component organization   *BUB1*, *PAX5*, *NGFR*, *MMP14*, *TTC3*, *SPTAN1*                                                                   .002
  0045596   Negative regulation of cell differentiation              *CAL1A1*, *NF1*, *CREBBP*, *ZBTB16, NGFR*, *PRDM16*, *TTC3*                                                         .002
  0042981   Regulation of apoptosis                                  *PTPRC*, *ESR1*, *ZBTB16*, *STAT1*, *BCL2L10*, *PROC*, *TNFRSF9*, *CASP6*, *KRAS*, *SOS2*, *NGFR*, *TRAF4*, *NF1*   .003
  0006915   Apoptosis                                                *SATA1*, *CASP6*, *TSC22D3*, *KRAS*, *SOS2*, *ZBTB16*, *NGFR*, *GADD45B, AHR*, *TRAF4*, *BCL2L10*                   .003
  0043067   Regulation of programmed cell death                      *PTPRC*, *ESR1*, *ZBTB16*, *STAT1*, *BCL2L10*, *PROC*, *TNFRSF9*, *CASP6*, *KRAS*, *SOS2*, *NGFR*, *TRAF4*, *NF1*   .003
  0010941   Regulation of cell death                                 *PTPRC*, *ESR1*, *ZBTB16*, *STAT1*, *BCL2L10*, *PROC*, *TNFRSF9*, *CASP6*, *KRAS*, *SOS2*, *NGFR*, *TRAF4*, *NF1*   .003
  0012501   Programmed cell death                                    *SATA1*, *CASP6*, *TSC22D3*, *KRAS*, *SOS2*, *ZBTB16*, *NGFR*, *GADD45B*, *AHR*, *TRAF4*, *BCL2L10*                 .003
  0043627   Response to estrogen stimulus                            *CASP6*, *SOCS1*, *ESR1*, *TSHB*, *MMP14*                                                                           .004
  0008283   Cell proliferation                                       *CALCA*, *PTPRC*, *COL4A3BP*, *CREBBP*, *BUB1*, *PELO*, *BOP1*, *MMP14*, *ISG20*                                    .004
  0009725   Response to hormone stimulus                             *SOCS1*, *ESR1*, *MMP14*, *STAT1*, *COL1A1*, *TSHB*, *KRAS*, *CASP6*                                                .006
  0019221   Cytokine-mediated signaling pathway                      *STAT6*, *KRAS*, *SOCS1*, *STAT1*                                                                                   .008
  0045637   Regulation of myeloid cell differentiation               *CALCA*, *IKZF1*, *ZBTB16*, *PRDM16*                                                                                .008

Pathway Enrichment Analysis
---------------------------

Only 1 pathway were screened out in our study, namely the Janus kinase (JAK)--signal transducer and activator of transcription (STAT) (JAK-STAT) pathway (*P* = .009). The DEGs that participated in this pathway were *STAT1*, *STAT6*, *SOS2*, and *SOCS1* (**[Figure 3](#F3){ref-type="fig"}A**). The signal transduction process in this JAK-STAT signaling pathway is shown in **[Figure 3](#F3){ref-type="fig"}B**.

![A, JAK-STAT signaling pathway in interaction network. B, Working hypothesis, showing signal transduction process in pathway. The yellow boxes in A represent the DEGs.](jls0011432660003){#F3}

Small-Molecule Drugs
--------------------

A total of 14 small molecules with a highly significant correlation are shown in **[Table 2](#T2){ref-type="table"}**, including 6 negatively related molecules and 8 positively related molecules. Among these molecules, luteolin---with the highest correlation (score of 0.887)---had the potential to be the small-molecule drug for kidney diseases.

###### 

Enriched Significant Small-Molecule Drugs

  CMap Name             Score     *P* Value
  --------------------- --------- -----------
  Prestwick-691         --0.877   .004
  Cromoglycic acid      --0.876   .031
  Isometheptene         --0.852   .001
  Trihexyphenidyl       --0.852   .006
  Disopyramide          --0.826   .012
  Atracurium besylate   --0.824   .011
  8-Azaguanine          0.818     .002
  Fenoterol             0.824     .011
  Phenoxybenzamine      0.829     .001
  Propylthiouracil      0.831     .001
  Chrysin               0.846     .007
  0297417--0002B        0.861     .005
  Medrysone             0.871     .000
  Luteolin              0.887     .000

DISCUSSION
==========

In this study we compared the gene expression profiles of kidneys recovered by LDN with CO~2~ pneumoperitoneum and those of open donor control kidneys. A total of 285 DEGs, including 148 down-regulated genes and 137 up-regulated genes, were identified. In addition, about 13 GO terms were screened out, and the most significant term was response to steroid hormone stimulus. A total of 7 DEGs were in this term, including *CASP6*, *KRAS*, *SOCS1*, *ESR1*, *TSHB*, *COL1A1*, and *MMP14*.

*KRAS* is a central player in intracellular signaling. It may be activated by the epidermal growth factor receptor or possibly other receptor tyrosine kinases. Through interaction with phosphatidylinositol-3 kinase and activation of the downstream effectors such as mammalian target of rapamycin, *KRAS* indirectly modulates cell survival.^[@B25]^ Through the Braf/mitogen-activated protein kinase pathway, it also influences cell proliferation.^[@B26]^

As part of a negative-feedback regulation, *SOCS1* down-regulates cytokine signaling through direct inhibition of the JAK tyrosine kinase and the signaling cascade of activated cytokine receptors, thereby attenuating cytokine-initiated signal transduction.^[@B27]^ Moreover, other studies have shown that *SOCS1* also down-regulates toll receptor signaling through direct and indirect mechanisms. Both cytokine receptor and toll receptor signaling pathways mediate important functions in survival, maturation, and differentiation of various types of cells and in the regulation of immune function.^[@B28]^

The protein product of *ESR1*, estrogen receptor α, is a ligand-activated transcription factor that plays an essential role in directing tissue-specific gene expression.^[@B29]^ *COL1A1* is a pro-fibrogenic extracellular matrix gene. Its protein product collagen-associated proteoglycan, which belongs to an extracellular matrix family, was up-regulated at the active/chronic inflammatory processes that accompany tissue damage.^[@B30]^ Matrix metalloproteinases that cleave interstitial collagens also play a crucial role in regulating matrix remodeling.^[@B31]^ *MMP14* (MT1-MMP) is a pericellular type I collagenase that is critical for the postnatal development of the mesenchyme.^[@B32]^ In our study *COL1A1* and *MMP14* were both up-regulated. This indicated that proteolytic collagen turnover is active in the LDN kidney tissues.

In addition, the JAK-STAT signaling pathway was identified as the most significant pathway and the DEGs that participated in this pathway were *STAT6*, *SOCS1*, *SOS2*, and *STAT1*. Members of the signal transducers and STATs are major substrates of JAKs.^[@B33]^ *STAT3*, *STAT1/4*, and *STAT6* are essential for differentiation of Th17, Th1, and Th2, respectively.^[@B34]^ *STAT1* has been previously associated with certain kidney diseases. The *SOS2* (salt overly sensitive 2) gene encodes a serine/threonine-type protein kinase, which has the potential to activate *SOS1*.^[@B35]^ The suppressors of cytokine signaling family members, including *SOCS1* to *SOCS7* in mammals, are important regulators of cytokine signaling pathways.^[@B36]^ Nakajima et al^[@B37]^ have shown that *STAT1* is activated by proteinuria in proximal tubular cells. Our results are consistent with the previous study, which suggests that these DEGs may induce kidney diseases by affecting the JAK-STAT signaling pathway. In a word, this activation results in the production of cytokines and growth factors, as well as the induction of immune responses, subsequently leading to kidney diseases.

Furthermore, luteolin---which had the highest connectivity---was screened out as a small-molecule drug in our research. Luteolin is a natural antioxidant with less pro-oxidant potential than the flavonol quercetin, the best-studied flavonoid, but apparently with a better safety profile. It displays excellent radical scavenging and cytoprotective properties, especially when tested in complex biological systems in which it can interact with other antioxidants like vitamins. Luteolin displays specific anti-inflammatory effects at micromolar concentrations, which are only partly explained by its antioxidant capacities.^[@B38]^ The anti-inflammatory activity includes activation of antioxidative enzymes, suppression of the Nuclear Factor-kappa B pathway, and inhibition of proinflammatory substances. In vivo, luteolin reduced increased vascular permeability and was effective in animal models of inflammation after parenteral and oral application.^[@B38]^ In our study we showed that luteolin may have the potential to treat kidney diseases.

In conclusion, the expression profile was compared between LDN and open control kidneys, and the significant DEGs and small-molecule drug luteolin were identified. Laparoscopy and CO~2~ pneumoperitoneum cause an up-regulation of genes associated with acute inflammation and immune injury, which could potentially result in renal injury and an enhanced immune response in the recipient after transplant. Our findings may help researchers to understand kidney diseases more profoundly and develop novel therapeutic drugs for these diseases. However, more investigations should be conducted to explore the pathogenesis of kidney diseases and develop more drugs to combat them.
